礼来新一代减肥针：体重可以减掉1/4

Core Insights - The latest trial data indicates that Eli Lilly's new weight loss drug, retatrutide, can help participants lose an average of nearly 25% of their body weight, potentially making it the most effective weight loss medication to date [1] - The highest dose group (12 mg) achieved a weight reduction of 23.7% over 68 weeks, with a significant decrease in knee pain scores by 62.6% [1] - Eli Lilly's results exceeded Wall Street's expectations, which predicted a weight loss range of 20% to 23% and a knee pain score reduction of 50% [1] Mechanism of Action - Retatrutide works by combining three different gut hormones: GIP, GLP-1, and glucagon, giving it an advantage over Eli Lilly's Zepbound and Novo Nordisk's Wegovy [2] Patient Outcomes - Some patients reported complete relief from knee pain by the end of the trial [3] - Eli Lilly's President of Cardiometabolic Health, Kenneth Custer, stated that retatrutide is expected to be an important option for patients with significant weight loss needs and related complications, such as knee osteoarthritis [3] - The trial is part of a series of studies aimed at testing retatrutide's effects on obesity and related diseases, with results expected to be published starting next year [3] Target Patient Profile - The drug is particularly suitable for patients with very high BMI or obesity-related complications who require significant weight loss [3] Side Effects - Approximately 18% of patients in the highest dose group withdrew from the trial due to noticeable side effects, which included nausea, diarrhea, and constipation [3] - Over 20% of high-dose patients experienced dysesthesia, an uncomfortable or abnormal nerve sensation, although most side effects were mild and rarely led to discontinuation of the drug [3] Market Position - The latest results are expected to further solidify Eli Lilly's leading position in the weight loss drug market, with Zepbound currently being the most popular weight loss medication [4] - The company is racing to develop more effective, easier-to-use, or less side-effect-prone new drugs [4]